Food and Drug Law Journal, Vol. 66, No. 3, 2011
45 Pages Posted: 16 Sep 2011
The Biologics Price Competition and Innovation Act of 2009 (“Biosimilars Act”) 1 is for the field of pharmaceutical products the single most important legislative development since passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (“Hatch-Waxman Act”),2 on which portions of the Biosimilars Act are clearly patterned. Congress revised section 351 of the Public Health Service Act (PHSA) to create a pathway for FDA approval of “biosimilar” biological products. Each biosimilar applicant is required to cite in its application a “reference product” that was approved on the basis of a full application containing testing data and manufacturing information, which is owned and was submitted by another company and much of which constitutes trade secret information subject to constitutional protection. Because the Biosimilars Act authorizes biosimilar applicants to cite these previously approved applications, the implementation of the new legislative scheme raises critical issues under the Fifth Amendment of the Constitution, pursuant to which private property - trade secrets included - may not be taken for public use, without “just compensation.” FDA must confront those issues as it implements the scheme set out in the Biosimilars Act. This article will discuss these issues, after providing a brief overview of the Biosimilars Act and a more detailed examination of the law of trade secrets.
Suggested Citation: Suggested Citation
Epstein, Richard A., The Constitutional Protection of Trade Secrets and Patents Under the Biologics Price Competition and Innovation Act of 2009. Food and Drug Law Journal, Vol. 66, No. 3, 2011 ; NYU Law and Economics Research Paper No. 11-30. Available at SSRN: https://ssrn.com/abstract=1927940
By David Levine
By Josh Lerner
By David Levine